Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need. Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Curran, Catherine
  • Pond, Gregory
  • Kazakova, Vera
  • Grivas, Petros
  • Diamantopoulos, Leonidas Nikolaos
  • Alva, Ajjai Shivaram
  • Su, Christopher
  • Jain, Rohit K
  • Tandon, Ankita
  • Zhang, Jingsong
  • Necchi, Andrea
  • Marandino, Laura
  • Merchan, Jaime R
  • Plastini, Trisha M
  • Sonpavde, Guru

publication date

  • May 20, 2020